AAAAAA

   
Results: 1-7 |
Results: 7
Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models
Authors: Wen, SF Xie, L McDonald, M DiGiacomo, R Chang, A Gurnani, M Shi, B Liu, SX Indelicato, SR Hutchins, B Nielsen, LL
Citation: Sf. Wen et al., Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models, CANC GENE T, 7(11), 2000, pp. 1469-1480
Performance of crossbred cattle and comparison of sires evaluation methodsunder organized farm condition
Authors: Sahana, G Gurnani, M
Citation: G. Sahana et M. Gurnani, Performance of crossbred cattle and comparison of sires evaluation methodsunder organized farm condition, I J ANIM SC, 70(4), 2000, pp. 409-414
Derivation and initial characterization of a mouse mammary tumor cell linecarrying the polyomavirus middle T antigen: Utility in the development of novel cancer therapeutics
Authors: Nielsen, LL Gurnani, M Shi, B Terracina, G Johnson, RC Carroll, J Mathis, JM Hajian, G
Citation: Ll. Nielsen et al., Derivation and initial characterization of a mouse mammary tumor cell linecarrying the polyomavirus middle T antigen: Utility in the development of novel cancer therapeutics, CANCER RES, 60(24), 2000, pp. 7066-7074
Repeatability of auxiliary sire indices with different progeny group size
Authors: Sahana, G Gurnani, M
Citation: G. Sahana et M. Gurnani, Repeatability of auxiliary sire indices with different progeny group size, I J ANIM SC, 69(10), 1999, pp. 816-819
Adenovirus mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer
Authors: Gurnani, M Lipari, P Dell, J Shi, B Nielsen, LL
Citation: M. Gurnani et al., Adenovirus mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer, CANC CHEMOT, 44(2), 1999, pp. 143-151
Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models
Authors: Nielsen, LL Shi, B Hajian, G Yaremko, B Lipari, P Ferrari, E Gurnani, M Malkowski, M Chen, JP Bishop, WR Liu, M
Citation: Ll. Nielsen et al., Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models, CANCER RES, 59(23), 1999, pp. 5896-5901
The use of laser scanning cytometry to assess depth of penetration of adenovirus p53 gene therapy in human xenograft biopsies
Authors: Grace, MJ Xie, L Musco, ML Cui, S Gurnani, M DiGiacomo, R Chang, A Indelicato, S Syed, J Johnson, R Nielsen, LL
Citation: Mj. Grace et al., The use of laser scanning cytometry to assess depth of penetration of adenovirus p53 gene therapy in human xenograft biopsies, AM J PATH, 155(6), 1999, pp. 1869-1878
Risultati: 1-7 |